Company news: Pfizer and Bristol-Myers Squibb

Share this article:

The FDA granted priority review status to Eliquis (apixaban), the novel oral anticoagulant being developed by Pfizer and Bristol-Myers Squibb, the firms said. The PDUFA goal date for a decision by the FDA is March 28, 2012.

The FDA issued a draft Blueprint for educating doctors on opioid drugs including long-acting and extended-release brand name and generic products. The blueprint contains core messages intended for use by continuing education providers to develop educational materials to train prescribers under the required risk evaluation and mitigation strategy (REMS) for these products. The FDA is seeking stakeholder input on the document until December 7.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.